A new combination of drugs could help delay the advancement of a deadly form of prostate cancer in those with an advanced form of the disease, new research has found. The “striking” findings showed an ...

As reports surface that the UK’s national screening committee are set to reject proposals for any national prostate screening programme, experts warn that the decision, if followed through with, puts ...

The phase 3 NRG GU-005 trial did not show a DFS benefit for SBRT vs IMRT in intermediate-risk prostate cancer, but SBRT decreased rectal toxicity. Stereotactic body radiation therapy (SBRT) preserves ...

Consider this a PSA about PSA. Prostate cancer is the most common cancer in US men, excluding skin cancer, and the second-leading cause of male cancer deaths, after lung cancer. One in 6 men will be ...

Prostate cancer is the second-leading cause of cancer death in American men. About 1 in 8 men will be diagnosed with prostate cancer in their lifetime, and the risk varies depending on age and race.

Please provide your email address to receive an email when new articles are posted on . A new model showed greater accuracy at predicting prostate cancer mortality vs. existing tools. It incorporates ...

The NRG Oncology NRG-GU009 (PREDICT-RT) study evaluating intensified and de-intensified concurrent radiation regimens based on the genomic risk of patients with high-risk prostate cancer completed ...

Having a prostate-specific antigen (PSA) test result above 4.0 ng/mL is considered abnormal and it is worth closer testing, a physician said yesterday, as he suggested individuals with a family ...